Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
09 August 2018Website:
http://www.vaccinex.comNext earnings report:
20 November 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Wed, 20 Nov 2024 23:45:55 GMTDividend
Analysts recommendations
Institutional Ownership
VCNX Latest News
Pepinemab appears to enhance clinical activity of immune checkpoint inhibitors via induction of mature tertiary lymphoid structures in tumors of patients with HPV-negative head and neck cancer. Pepinemab appears to enhance clinical activity of immune checkpoint inhibitors via induction of mature tertiary lymphoid structures in tumors of patients with HPV-negative head and neck cancer.
ROCHESTER, N.Y., Sept. 18, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX) (“Vaccinex” or the “Company”), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease by blocking astrogliosis and neuroinflammation through the inhibition of SEMA4D, announced today the entry into definitive agreements for the immediate exercise of outstanding warrants to purchase an aggregate of 1,067,492 shares of common stock (the “Existing Warrants”) at the reduced exercise price of $5.636 per share, resulting in the issuance of 827,483 shares and the pre-funding of 240,009 shares.
ROCHESTER, N.Y., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Vaccinex (Nasdaq: VCNX) today provided an update on new clinical findings from its SIGNAL-AD Phase 1b/2 trial of pepinemab antibody in Alzheimer's disease.
Company expects to lock database in June andremains on track to report key outcomes later in July. Pepinemab targets astrocyte reactivity and neuroinflammation,believed to be key drivers of neurodegeneration.
Final patient completed their last visit in the SIGNAL-AD Phase 2a trial evaluating pepinemab for Alzheimer's Disease in early June 2024. $8.2 million of fresh funding was secured in the first quarter.
Vaccinex (NASDAQ: VCNX ) stock is climbing higher on Friday after the clinical-stage biotechnology company announced insider buying. These insider trading actions were revealed by Vaccinex in a series of filings with the Securities and Exchange Commission (SEC).
Fintel reports that Fcmi Parent has filed a 13D/A form with the SEC disclosing ownership of 23.49MM shares of Vaccinex Inc (VCNX).
What type of business is Vaccinex?
Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat cancer, neurodegenerative diseases, and autoimmune disorders. The company's lead drug candidate, pepinemab, a humanized monoclonal antibody that binds and blocks the activity of SEMA4D. It is developing Pepinemab, which is in phase 2 study for treatment of Alzheimer's disease and has completed phase 2 study for treatment of Huntington's disease; Pepinemab in combination with Pembrolizumab in phase 2 study for head and neck cancer, Avelumab in phase 2 study for pancreatic cancer, and completed phase 2 study with Avelumab for non-small cell lung cancer; and Pepinemab in combination with Nivolumab completed phase 2 study for melanoma, and trastuzumab and DC vaccine in phase 2 study for breast cancer. The company has also developed ActivMAb, an antibody drug discovery platform based on a novel method for complex targets, such as multi-pass membrane receptors or large and diverse libraries of full-length human monoclonal antibodies on the surface of pox viruses. It has collaborations with Merck Sharp & Dohme; Ares Trading S.A.; The Children's Hospital of Philadelphia; Emory University; Huntington Study Group; H. Lee Moffitt Cancer Center and Research Institute, Inc; Catalent Pharma Solutions, LLC; Surface Oncology, Inc.; and Pharmaceutical and Biotech Co. The company was incorporated in 2001 and is headquartered in Rochester, New York.
What sector is Vaccinex in?
Vaccinex is in the Healthcare sector
What industry is Vaccinex in?
Vaccinex is in the Biotechnology industry
What country is Vaccinex from?
Vaccinex is headquartered in United States
When did Vaccinex go public?
Vaccinex initial public offering (IPO) was on 09 August 2018
What is Vaccinex website?
https://www.vaccinex.com
Is Vaccinex in the S&P 500?
No, Vaccinex is not included in the S&P 500 index
Is Vaccinex in the NASDAQ 100?
No, Vaccinex is not included in the NASDAQ 100 index
Is Vaccinex in the Dow Jones?
No, Vaccinex is not included in the Dow Jones index
When was Vaccinex the previous earnings report?
No data
When does Vaccinex earnings report?
The next expected earnings date for Vaccinex is 20 November 2024